RESUMEN
Prevalence and predictors of masked arterial hypertension (AH) in patients receiving antihypertensive therapy (concealed treatment inefficacy--CTI) was studied on material of data base comprising 219 observations. Drugs from 5 groups were used. Prevalence of CTI AH with the use of various definitions was 8.1-17.4%. With the help of procedure of logistic regression analysis the following predictors of CTI were selected: (1) sociopsychological--high working capacity, high psychological abilities and social self feeling; (2) parameters of 24-hour BP profile--24-hour variability, variability during working period, minimal daytime BP level, time of maximal BP. According to our data CTI is most probable during treatment with calcium antagonists and beta-adrenoblockers.
Asunto(s)
Antihipertensivos/uso terapéutico , Presión Sanguínea/fisiología , Hipertensión/epidemiología , Adulto , Monitoreo Ambulatorio de la Presión Arterial , Femenino , Humanos , Hipertensión/tratamiento farmacológico , Hipertensión/fisiopatología , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Retrospectivos , Federación de Rusia/epidemiología , Resultado del TratamientoRESUMEN
Effects of the standard doses of telmisartan (20-80 mg) and enalapril (5-10 mg) on the arterial pressure (AP, circadian monitoring), psychological state (Minnesota Multiphase Personality Inventory questionnaire, Russian version), and quality of life (General Well-Being Questionnaire) were studied in a randomized, parallel group trial in 30 patients with stable, soft-to-moderate arterial hypertension. The initial control 2-week period was followed by a 12-week period of active therapy. It was established that the long-term administration of both drugs in standard doses produced comparable antihypertensive effect, reliably reducing the averaged AP characteristics. Both drugs also improved the quality of life: enalapril influenced predominantly the psychological score, while telmisartan increased both psychological score and social score. Long-term administration of both drugs had a positive effect on the psychological state of hypertensive patients.
Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/administración & dosificación , Antihipertensivos/administración & dosificación , Bencimidazoles/administración & dosificación , Benzoatos/administración & dosificación , Enalapril/administración & dosificación , Hipertensión/tratamiento farmacológico , Hipertensión/psicología , Adulto , Anciano , Presión Sanguínea/efectos de los fármacos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Calidad de Vida/psicología , Encuestas y Cuestionarios , TelmisartánRESUMEN
AIM: To compare efficacy and safety of nifedipin-retard (cordaflex-retard, Egis, Hungary) used in monotherapy and in combination with metoprolol (egilok, Egis, Hungary) in patients with arterial hypertension (AH). MATERIAL AND METHODS: The study included 20 patients with AH stage I-II (12 males, 8 females, mean age 57.3 years, mean duration of the disease 8.6 years). Nifedipin-retard was given in a daily dose 40 mg/day (20 mg twice a day) in monotherapy and 20 mg/day in combination with metoprolol which was administered 50 mg twice a day (a daily dose 100 mg/day). The control examination consisted of a physical examination, measurement of arterial pressure (AP) by Korotkov, registration of heart rate, ECG, 24-h AP monitoring, echocardiography. RESULTS: By 24-h AP monitoring, a 4-week treatment with nifedipin-retard alone resulted in lowering of systolic arterial pressure. The combined treatment produced a more pronounced fall both in systolic and diastolic pressure. Diastolic left-ventricular function improved in combined therapy. Side effects observed in nifedipin-retard monotherapy got much more weaker when this drug combined with metoprolol. CONCLUSION: Combination of nifedipin-retard with metoprolol provides better clinical response and tolerance than monotherapy with nifedipin-retard.